Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 1217389 plus weekly paclitaxel dose-escalation study in advanced malignancies
NL-OMON45121Phase 1Not yet recruiting
- Sponsor
- Bayer
- Start
- Apr 2015
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BAY 1217389 and paclitaxel in Nonhematologic neoplasms and triple-negative breast cancer (TNBC), sponsored by Bayer. Primary endpoints: Maximum tolerated dose, Safety and tolerability and 2 more. Planned start Apr 2015; status: not yet recruiting.
02
Drugs
BAY 1217389paclitaxel
03
Conditions
Nonhematologic neoplasmstriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NL-OMON45121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45121.